Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Erratum: Vol. 60, No. RR-1
Filetype[PDF-45.08 KB]


Details:
  • Alternative Title:
    MMWR Morb Mortal Wkly Rep
  • Description:
    In the Recommendations and Reports "Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza" (January 21, 2011, Vol. 60, No. RR-1, https://www.cdc.gov/mmwr/pdf/rr/rr6001.pdf), on page 8, in the first column, in the second paragraph, in the second sentence, the term "pneumonia" was used rather than "lower respiratory tract complications leading to antibiotic use." The corrected sentence should read, "In a study that combined data from 10 clinical trials, the risk for lower respiratory tract complications leading to antibiotic use among those participants with laboratory-confirmed influenza receiving oseltamivir treatment was approximately 50% lower than among those persons receiving a placebo and 34% lower among patients at risk for complications (p<0.05 for both comparisons) (22)."
  • Subject:
  • Pubmed ID:
    28683060
  • Pubmed Central ID:
    PMC5726241
  • Document Type:
    Journal Article
  • Collection(s):
    Morbidity and Mortality Weekly Report (MMWR)
  • Main Document Checksum:
No Related Documents.
You May Also Like:
  1. Coming Soon
    SUPPLEMENTARY FIGURE 1. Weekly provider order comparisons, human papilloma virus (HPV) vaccine (A), tetanus and diphtheria toxoids (TD) and tetanus and diphtheria toxoids and acellular pertussis vaccines (TDAP) vaccines (B), and meningococcal conjugate vaccine (MCV4) (Menveo) vaccine (C) — United States, fiscal years 2019 and 2020
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    08/21/2020
    Series:
    MMWR. Morbidity and mortality supplementary materials
    Description:
    MMWR Supplementary Table for Volume 69 no.32
    Public Access
    Available on:
    August 18, 2020
  2. Coming Soon
    SUPPLEMENTARY FIGURE 1.
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    08/21/2020
    Series:
    MMWR. Morbidity and mortality supplementary materials
    Description:
    MMWR Supplementary Table for Volume 69 no.32
    Public Access
    Available on:
    August 18, 2020
  3. Coming Soon
    SUPPLEMENTARY TABLE. Estimated vaccination coverage with selected vaccines and doses* among adolescents aged 13–17 years† (N = 18,788) by HHS region, state, selected local area, or territory — National Immunization Survey–Teen (NIS-Teen), United States, 2019
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    08/21/2020
    Series:
    MMWR. Morbidity and mortality supplementary materials
    Description:
    MMWR Supplementary Table for Volume 69 no.32
    Public Access
    Available on:
    August 18, 2020
  4. Coming Soon
    Sources of Sodium Potassium Supplement
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    08/14/2020
    Series:
    MMWR. Morbidity and mortality supplementary materials
    Description:
    MMWR Supplementary Table for Volume 69 no.32
    Public Access
    Available on:
    August 11, 2020
  5. Staffing resources : get and keep America open: supporting states, tribes, localities, and territories
    Corporate Authors:
    National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
    Published Date:
    August 8, 2020
    Description:
    Updated Aug. 7, 2020Strengthening the public health workforce. Enhancing frontline public health capacity in state, local, tribal, and territorial health departments to intensify the coordinated response to COVID-19 is critical.
    File Type:
    Filetype[PDF - 487.80 KB]